JP5656183B2 - 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 - Google Patents
滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 Download PDFInfo
- Publication number
- JP5656183B2 JP5656183B2 JP2009525260A JP2009525260A JP5656183B2 JP 5656183 B2 JP5656183 B2 JP 5656183B2 JP 2009525260 A JP2009525260 A JP 2009525260A JP 2009525260 A JP2009525260 A JP 2009525260A JP 5656183 B2 JP5656183 B2 JP 5656183B2
- Authority
- JP
- Japan
- Prior art keywords
- mesenchymal stem
- stem cells
- cartilage
- defect
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 171
- 210000000845 cartilage Anatomy 0.000 title claims description 139
- 230000008929 regeneration Effects 0.000 title description 6
- 238000011069 regeneration method Methods 0.000 title description 6
- 230000007547 defect Effects 0.000 claims description 163
- 210000004027 cell Anatomy 0.000 claims description 146
- 230000005499 meniscus Effects 0.000 claims description 36
- 210000002966 serum Anatomy 0.000 claims description 25
- 210000001258 synovial membrane Anatomy 0.000 claims description 25
- 230000006378 damage Effects 0.000 claims description 14
- 206010061762 Chondropathy Diseases 0.000 claims description 13
- 230000004069 differentiation Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 206010007710 Cartilage injury Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 6
- 210000000968 fibrocartilage Anatomy 0.000 claims description 5
- 210000003035 hyaline cartilage Anatomy 0.000 claims description 5
- 201000009859 Osteochondrosis Diseases 0.000 claims description 4
- 206010031264 Osteonecrosis Diseases 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- 238000002054 transplantation Methods 0.000 description 31
- 210000001185 bone marrow Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 239000002609 medium Substances 0.000 description 22
- 210000001612 chondrocyte Anatomy 0.000 description 21
- 208000006735 Periostitis Diseases 0.000 description 19
- 210000003460 periosteum Anatomy 0.000 description 19
- 210000000988 bone and bone Anatomy 0.000 description 17
- 239000000499 gel Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000011065 in-situ storage Methods 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 230000022159 cartilage development Effects 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 239000000512 collagen gel Substances 0.000 description 10
- 210000003127 knee Anatomy 0.000 description 10
- 229950003937 tolonium Drugs 0.000 description 10
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002648 chondrogenic effect Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 230000003848 cartilage regeneration Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000055008 Matrilin Proteins Human genes 0.000 description 6
- 108010072582 Matrilin Proteins Proteins 0.000 description 6
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 6
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 238000002324 minimally invasive surgery Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 210000005222 synovial tissue Anatomy 0.000 description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002804 Osteochondritis Diseases 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 230000002293 adipogenic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- IJRJBQGVWNVZSA-UHFFFAOYSA-N dilC18(3)(1+) Chemical compound CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C IJRJBQGVWNVZSA-UHFFFAOYSA-N 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000000281 joint capsule Anatomy 0.000 description 3
- 229960004184 ketamine hydrochloride Drugs 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 210000001316 polygonal cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82313806P | 2006-08-22 | 2006-08-22 | |
| US60/823,138 | 2006-08-22 | ||
| PCT/JP2007/066708 WO2008023829A1 (en) | 2006-08-22 | 2007-08-22 | Application of synovium-derived mesenchymal stem cells (mscs) for cartilage or meniscus regeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145146A Division JP5928961B2 (ja) | 2006-08-22 | 2014-07-15 | 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010501547A JP2010501547A (ja) | 2010-01-21 |
| JP2010501547A5 JP2010501547A5 (enExample) | 2010-10-07 |
| JP5656183B2 true JP5656183B2 (ja) | 2015-01-21 |
Family
ID=39106908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525260A Active JP5656183B2 (ja) | 2006-08-22 | 2007-08-22 | 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 |
| JP2014145146A Active JP5928961B2 (ja) | 2006-08-22 | 2014-07-15 | 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145146A Active JP5928961B2 (ja) | 2006-08-22 | 2014-07-15 | 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100178274A1 (enExample) |
| JP (2) | JP5656183B2 (enExample) |
| WO (1) | WO2008023829A1 (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022004878A1 (ja) | 2020-07-03 | 2022-01-06 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法 |
| WO2022004879A1 (ja) | 2020-07-03 | 2022-01-06 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法 |
| WO2022075294A1 (ja) | 2020-10-07 | 2022-04-14 | 富士フイルム株式会社 | 関節治療用細胞製剤の製造方法、関節治療用細胞製剤および間葉系幹細胞の培養方法 |
| WO2023286305A1 (ja) | 2021-07-15 | 2023-01-19 | 富士フイルム株式会社 | 細胞の品質管理方法及び細胞を製造する方法 |
| WO2023286819A1 (ja) | 2021-07-15 | 2023-01-19 | 富士フイルム株式会社 | 特定細胞の品質管理方法及び特定細胞を製造する方法 |
| WO2023032945A1 (ja) | 2021-08-31 | 2023-03-09 | 富士フイルム株式会社 | 関節症治療剤、及び関節症治療剤の製造方法 |
| WO2023249104A1 (ja) | 2022-06-24 | 2023-12-28 | 富士フイルム株式会社 | 細胞製品を提供するためのシステム |
| WO2025206252A1 (ja) * | 2024-03-29 | 2025-10-02 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞、その製造方法、およびその利用 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| JP5843189B2 (ja) * | 2011-03-15 | 2016-01-13 | 国立大学法人名古屋大学 | Ｓｄｆ−１阻害剤を含有した軟骨組織再生用組成物 |
| JP6502857B2 (ja) * | 2013-01-14 | 2019-04-17 | スクリップス ヘルス | 組織アレイプリンティング |
| CN105392489B (zh) | 2013-08-01 | 2019-11-22 | 智再如股份有限公司 | 软骨损伤治疗剂及其制造方法 |
| US11497830B2 (en) | 2014-03-14 | 2022-11-15 | Scripps Health | Electrospinning of cartilage and meniscus matrix polymers |
| KR101641770B1 (ko) * | 2014-06-23 | 2016-07-22 | 씨제이제일제당 (주) | O-아세틸 호모세린을 생산하는 미생물 및 상기 미생물을 이용하여 o-아세틸 호모세린을 생산하는 방법 |
| CN104357385A (zh) * | 2014-11-17 | 2015-02-18 | 四川大学华西医院 | 一种半月板组织来源的间充质干细胞及其制备方法和鉴定 |
| EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
| US11497831B2 (en) | 2016-05-26 | 2022-11-15 | Scripps Health | Systems and methods to repair tissue defects |
| WO2018131673A1 (ja) * | 2017-01-13 | 2018-07-19 | 公立大学法人首都大学東京 | 新規組織再生材料およびその製造方法 |
| US12453743B2 (en) | 2018-05-30 | 2025-10-28 | Direct Biologics, Llc | Mesenchymal stem cell (MSC) growth factor and extracellular vesicle preparation in frozen or powdered form and methods of use |
| KR102223043B1 (ko) * | 2018-09-28 | 2021-03-08 | 주식회사 히에라바이오 | 활액막 유래 중간엽 줄기세포 및 그의 용도 |
| WO2020196233A1 (ja) * | 2019-03-26 | 2020-10-01 | 国立大学法人東京医科歯科大学 | 軟骨組織の再生を促進するための組成物 |
| EP3999083A4 (en) | 2019-07-18 | 2023-07-26 | Direct Biologics LLC | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| CN117355314A (zh) * | 2021-03-12 | 2024-01-05 | 富士胶片株式会社 | 关节病治疗剂的制造方法及关节病治疗剂 |
| CN119235920B (zh) * | 2024-12-06 | 2025-06-24 | 浙江大学 | 一种用于关节软骨损伤修复的mfap5阳性滑膜衬里层干细胞及其鉴定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527916A (en) * | 2001-01-30 | 2006-10-27 | Orthogene Inc | Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells |
| JP2003199816A (ja) * | 2002-01-10 | 2003-07-15 | Takehisa Matsuda | 軟骨組織再生用補助材、軟骨組織再生用キット及び軟骨組織再生方法 |
| CA2530421C (en) * | 2003-06-27 | 2015-04-21 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
-
2007
- 2007-08-22 US US12/438,298 patent/US20100178274A1/en not_active Abandoned
- 2007-08-22 JP JP2009525260A patent/JP5656183B2/ja active Active
- 2007-08-22 WO PCT/JP2007/066708 patent/WO2008023829A1/en not_active Ceased
-
2014
- 2014-07-15 JP JP2014145146A patent/JP5928961B2/ja active Active
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022004878A1 (ja) | 2020-07-03 | 2022-01-06 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法 |
| WO2022004879A1 (ja) | 2020-07-03 | 2022-01-06 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法 |
| KR20230025800A (ko) | 2020-07-03 | 2023-02-23 | 후지필름 가부시키가이샤 | 활막 유래 간엽계 줄기 세포의 제조 방법 및 관절 치료용 세포 제제의 제조 방법 |
| KR20230025801A (ko) | 2020-07-03 | 2023-02-23 | 후지필름 가부시키가이샤 | 활막 유래 간엽계 줄기 세포의 제조 방법 및 관절 치료용 세포 제제의 제조 방법 |
| WO2022075294A1 (ja) | 2020-10-07 | 2022-04-14 | 富士フイルム株式会社 | 関節治療用細胞製剤の製造方法、関節治療用細胞製剤および間葉系幹細胞の培養方法 |
| KR20230058721A (ko) | 2020-10-07 | 2023-05-03 | 후지필름 가부시키가이샤 | 관절 치료용 세포 제제의 제조 방법, 관절 치료용 세포 제제 및 간엽계 줄기세포의 배양 방법 |
| WO2023286305A1 (ja) | 2021-07-15 | 2023-01-19 | 富士フイルム株式会社 | 細胞の品質管理方法及び細胞を製造する方法 |
| WO2023286819A1 (ja) | 2021-07-15 | 2023-01-19 | 富士フイルム株式会社 | 特定細胞の品質管理方法及び特定細胞を製造する方法 |
| WO2023032945A1 (ja) | 2021-08-31 | 2023-03-09 | 富士フイルム株式会社 | 関節症治療剤、及び関節症治療剤の製造方法 |
| WO2023249104A1 (ja) | 2022-06-24 | 2023-12-28 | 富士フイルム株式会社 | 細胞製品を提供するためのシステム |
| WO2025206252A1 (ja) * | 2024-03-29 | 2025-10-02 | 富士フイルム株式会社 | 滑膜由来間葉系幹細胞、その製造方法、およびその利用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014196354A (ja) | 2014-10-16 |
| US20100178274A1 (en) | 2010-07-15 |
| JP2010501547A (ja) | 2010-01-21 |
| JP5928961B2 (ja) | 2016-06-01 |
| WO2008023829A1 (en) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5656183B2 (ja) | 滑膜由来間葉幹細胞（ＭＳＣｓ）の軟骨・半月板再生への応用 | |
| Izuta et al. | Meniscal repair using bone marrow-derived mesenchymal stem cells: experimental study using green fluorescent protein transgenic rats | |
| Newman | Articular cartilage repair | |
| Lee et al. | Synovial membrane–derived mesenchymal stem cells supported by platelet-rich plasma can repair osteochondral defects in a rabbit model | |
| Kuroda et al. | Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells | |
| US6482231B1 (en) | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative | |
| Nishimori et al. | Repair of chronic osteochondral defects in the rat: a bone marrow-stimulating procedure enhanced by cultured allogenic bone marrow mesenchymal stromal cells | |
| Kayakabe et al. | Transplantation of autologous rabbit BM-derived mesenchymal stromal cells embedded in hyaluronic acid gel sponge into osteochondral defects of the knee | |
| US20040077079A1 (en) | Improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods | |
| González-Fernández et al. | Assessment of regeneration in meniscal lesions by use of mesenchymal stem cells derived from equine bone marrow and adipose tissue | |
| JP7350344B2 (ja) | ヒト誘導万能幹細胞から軟骨細胞のペレットを製造する方法およびその用途 | |
| Murata et al. | Osteochondral regeneration using scaffold-free constructs of adipose tissue-derived mesenchymal stem cells made by a bio three-dimensional printer with a needle-array in rabbits | |
| Gültekin et al. | Comparison of mesenchymal stem cell sheets and chondrocyte sheets in a rabbit growth plate injury model | |
| Montoya et al. | Clinical and experimental approaches to knee cartilage lesion repair and mesenchymal stem cell chondrocyte differentiation | |
| Cugat et al. | Particulated autologous chondral− platelet-rich plasma matrix implantation (PACI) for treatment of full-thickness cartilage osteochondral defects | |
| JP6958846B1 (ja) | 滑膜由来間葉系幹細胞の製造方法および関節治療用細胞製剤の製造方法 | |
| Goyal | Recent advances and future trends in articular cartilage repair | |
| CN106421917A (zh) | 制备用于软骨损伤修复的组合物的方法 | |
| CN105754937A (zh) | 一种促进软骨分化的细胞共培养体系及其制备方法 | |
| Jin et al. | Implantation of bone marrow-derived buffy coat can supplement bone marrow stimulation for articular cartilage repair | |
| TWI900599B (zh) | 源自滑膜之間葉系幹細胞之製造方法及關節治療用細胞製劑之製造方法 | |
| Zhou et al. | In Vitro Culture and Biological Characterization of Meniscal Fibrochondrocytes | |
| Meyerkort et al. | One-stage vs two-stage cartilage repair: a current review | |
| Wu | Chondrocyte Migration from Bioengineered Cartilage | |
| Benea | Innovative Materials and Techniques for Osteochondral Repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100820 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130905 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140715 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140909 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141031 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5656183 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |